Pulse Explore Journal Club Debates Trending Researchers Journals

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Withdrawal of Troglitazone and Cisapride | Synapse

May 3, 2000

View Full Paper

Withdrawal of Troglitazone and Cisapride

JHJane E. HenneyNational Academy of Medicine

Key Points

Key points are not available for this paper at this time.

Abstract

The FDA wishes to inform physicians of the removal from the market of troglitazone (Rezulin, Parke-Davis/Warner-Lambert Co, Morris Plains, NJ), a treatment for type 2 diabetes mellitus, and cisapride (Propulsid, Janssen Pharmaceutica Inc, Titusville, NJ), a treatment for severe heartburn.

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Jane E. Henney (Wed,) studied this question.

synapsesocial.com/papers/69f179c6b6126e0e7a728196 https://doi.org/https://doi.org/10.1001/jama.283.17.2228

Ask AI

Helpful

Bookmark

Share

View Full Paper